NASDAQ:VACC Vaccitech (VACC) Stock Price, News & Analysis → Crypto Market Preps For Trillions Worth of Inflows! (From Crypto 101 Media) (Ad) Free VACC Stock Alerts $2.33 -0.07 (-2.92%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$2.31▼$2.4050-Day Range$2.33▼$5.0052-Week Range$1.64▼$5.10Volume30,871 shsAverage Volume244,643 shsMarket Capitalization$89.81 millionP/E RatioN/ADividend YieldN/APrice Target$7.63 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Vaccitech alerts: Email Address Vaccitech MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside227.3% Upside$7.63 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.41) to ($2.74) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.52 out of 5 starsMedical Sector886th out of 939 stocksPharmaceutical Preparations Industry408th out of 435 stocks 3.3 Analyst's Opinion Consensus RatingVaccitech has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.63, Vaccitech has a forecasted upside of 227.3% from its current price of $2.33.Amount of Analyst CoverageVaccitech has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for VACC. Previous Next 0.0 Dividend Strength Dividend YieldVaccitech does not currently pay a dividend.Dividend GrowthVaccitech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VACC. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Vaccitech this week, compared to 0 articles on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vaccitech insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.00% of the stock of Vaccitech is held by insiders.Percentage Held by InstitutionsOnly 26.13% of the stock of Vaccitech is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Vaccitech are expected to decrease in the coming year, from ($2.41) to ($2.74) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vaccitech is -1.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vaccitech is -1.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVaccitech has a P/B Ratio of 0.36. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Huge AlertsTrending Stocks Sent To You In Real Time Sign up today and get instant access to our next stock alert! You do not want to miss out on this next pick! Our stock picks have been known to soar! Click To Get Our Next Alert About Vaccitech Stock (NASDAQ:VACC)Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious and autoimmunity diseases, and cancers. The company's therapeutic programs include VTP-300, which is in Phase 2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1b/2 clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.Read More VACC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VACC Stock News HeadlinesMarch 26, 2024 | americanbankingnews.comVaccitech (NASDAQ:VACC) Trading 7% Higher March 2, 2024 | seekingalpha.comArbutus Biopharma Corporation (ABUS) Q4 2023 Earnings Call TranscriptMarch 28, 2024 | MarketBeat (Ad)Your $200 account credit is about to expireUpdate to MarketBeat All Access and Save $300 on Your Annual SubscriptionJanuary 8, 2024 | markets.businessinsider.comPositive Clinical Outlook and Strong Capital Position Justify Buy Rating for Barinthus BiotherapeuticsJanuary 8, 2024 | finanznachrichten.deBarinthus Biotherapeutics: Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate MilestonesJanuary 5, 2024 | finance.yahoo.comBarinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate MilestonesDecember 22, 2023 | markets.businessinsider.comBuy Rating for Barinthus Biotherapeutics: Promising Pipeline and Strategic Partnerships Signal Investment OpportunityDecember 21, 2023 | markets.businessinsider.comBarinthus Biotherapeutics Collaborates With CEPI And University Of Oxford For New MERS VaccineMarch 28, 2024 | MarketBeat (Ad)Your $200 account credit is about to expireUpdate to MarketBeat All Access and Save $300 on Your Annual SubscriptionDecember 21, 2023 | finance.yahoo.comNew partnership aims to advance vaccine against MERS coronavirusDecember 13, 2023 | finance.yahoo.comInfluenza Vaccine Market to grow by USD 2.93 billion from 2022 to 2027; North America to account for 54% of market growth - TechnavioNovember 28, 2023 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: Barinthus Biotherapeutics (BRNS), Anavex Life Sciences (AVXL)November 15, 2023 | finance.yahoo.comBarinthus Biotherapeutics plc (BRNS)November 9, 2023 | finance.yahoo.comBarinthus Bio Reports Third Quarter 2023 Financial Results and Recent Corporate DevelopmentsNovember 8, 2023 | money.usnews.comBarinthus Biotherapeutics Plc. - ADRNovember 7, 2023 | msn.comBarinthus stock falls 18%, day after changing name from VaccitechNovember 6, 2023 | msn.comVaccitech rebrands as Barinthus, plans to present data at AASLD meetingNovember 6, 2023 | finance.yahoo.comVaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and CancerSeptember 28, 2023 | seekingalpha.comSIRI, EC and PBTS among pre-market losersSeptember 26, 2023 | 247wallst.comMorgan Stanley Downgrades VaccitechSeptember 26, 2023 | uk.finance.yahoo.comInnovative Therapeutic Cancer Vaccines Drive Unprecedented Growth in Global Cancer Vaccines Market to 2028September 26, 2023 | seekingalpha.comVaccitech surges despite Morgan Stanley downgradeSeptember 26, 2023 | finance.yahoo.comVaccitech plc (NASDAQ:VACC) surges 85%; individual investors who own 44% shares profited along with institutionsSeptember 25, 2023 | benzinga.comGlobal Cancer Vaccines Market to Skyrocket, Projected to Reach $12.1 Billion by 2028September 25, 2023 | marketwatch.comHealth Care Up on Defensive Bets -- Health Care RoundupSeptember 25, 2023 | msn.comMorgan Stanley Downgrades Vaccitech plc - ADR (VACC)September 25, 2023 | marketwatch.comVaccitech Shares Surge as Alliance Global Initiates CoverageSee More Headlines Receive VACC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaccitech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/12/2021Today3/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:VACC CUSIPN/A CIK1828185 Webwww.vaccitech.co.uk Phone44-18-6581-8808FaxN/AEmployees33Year FoundedN/APrice Target and Rating Average Stock Price Target$7.63 High Stock Price Target$12.00 Low Stock Price Target$3.25 Potential Upside/Downside+227.3%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$5.34 million Net Margins-409.18% Pretax Margin-442.00% Return on Equity-23.41% Return on Assets-20.85% Debt Debt-to-Equity RatioN/A Current Ratio15.26 Quick Ratio15.26 Sales & Book Value Annual Sales$13.42 million Price / Sales6.69 Cash Flow$0.12 per share Price / Cash Flow19.30 Book Value$6.52 per share Price / Book0.36Miscellaneous Outstanding Shares38,547,000Free Float36,234,000Market Cap$89.81 million OptionableNot Optionable Beta-0.40 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. William J. Enright MBA (Age 60)CEO & Director Comp: $916.62kMs. Sarah GilbertCo-FounderMr. Adrian Hill Ph.D.Co-Founder & Scientific AdvisorMs. Gemma Brown (Age 33)CFO & Company Secretary Mr. Chris Ellis (Age 63)Chief Operating Officer Dr. Nadege Pelletier Ph.D. (Age 45)Chief Scientific Officer Mr. Graham Griffiths (Age 44)Chief Business Officer Ms. Elizabeth Eagling-Vose M.B.A.Head of Clinical OperationsBernie McDonaldHead of IPGeoffrey LynnSenior Vice President of Synthetic ImmunotherapiesMore ExecutivesKey CompetitorsSpero TherapeuticsNASDAQ:SPROBarinthus BiotherapeuticsNASDAQ:BRNSAssertioNASDAQ:ASRTChimerixNASDAQ:CMRXCelularityNASDAQ:CELUView All CompetitorsInsiders & InstitutionsIpswich Investment Management Co. Inc.Sold 4,000 shares on 1/31/2024Ownership: 0.060%Joseph ScheerenBought 10,000 shares on 6/26/2023Total: $24,400.00 ($2.44/share)Robin WrightBought 13,750 shares on 5/25/2023Total: $36,575.00 ($2.66/share)View All Insider TransactionsView All Institutional Transactions VACC Stock Analysis - Frequently Asked Questions Should I buy or sell Vaccitech stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vaccitech in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" VACC shares. View VACC analyst ratings or view top-rated stocks. What is Vaccitech's stock price target for 2024? 2 equities research analysts have issued 1 year price targets for Vaccitech's shares. Their VACC share price targets range from $3.25 to $12.00. On average, they predict the company's share price to reach $7.63 in the next year. This suggests a possible upside of 227.3% from the stock's current price. View analysts price targets for VACC or view top-rated stocks among Wall Street analysts. How have VACC shares performed in 2024? Vaccitech's stock was trading at $3.69 at the beginning of the year. Since then, VACC shares have decreased by 36.9% and is now trading at $2.33. View the best growth stocks for 2024 here. How were Vaccitech's earnings last quarter? Vaccitech plc (NASDAQ:VACC) issued its quarterly earnings data on Friday, November, 12th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.25. The company earned $0.02 million during the quarter, compared to the consensus estimate of $1.65 million. Vaccitech had a negative net margin of 409.18% and a negative trailing twelve-month return on equity of 23.41%. When did Vaccitech IPO? Vaccitech (VACC) raised $110 million in an IPO on Friday, April 30th 2021. The company issued 6,500,000 shares at $16.00-$18.00 per share. Morgan Stanley, Jefferies, Barclays and William Blair served as the underwriters for the IPO and H.C. Wainwright & Co., LLC was co-manager. Who are Vaccitech's major shareholders? Vaccitech's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Ipswich Investment Management Co. Inc. (0.06%). Insiders that own company stock include Christopher Ellis, Graham Griffiths, Joseph Scheeren, Karen A Dawes, M&G Investment Management Ltd, Robin Wright, Sciences Innovation Plc Oxford and William Enright. View institutional ownership trends. How do I buy shares of Vaccitech? Shares of VACC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VACC) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaccitech plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.